Get the Stockscreener App
0.584
4.14%
0.024
Veru Inc stock is traded at $0.584, with a volume of 2.54M.
It is up +4.14% in the last 24 hours and down -20.92% over the past month.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
See More
Previous Close:
$0.56
Open:
$0.56
24h Volume:
2.54M
Relative Volume:
0.92
Market Cap:
$84.89M
Revenue:
$15.93M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.7787
EPS:
-0.75
Net Cash Flow:
$-59.50M
1W Performance:
-4.58%
1M Performance:
-20.92%
6M Performance:
-29.64%
1Y Performance:
+19.02%
1-Day Range:
$0.539
$0.5887
1-Week Range:
$0.534
$0.62
52-Week Range:
$0.3612
$1.92
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
0.581 | 84.89M | 15.93M | -64.59M | -59.50M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.01 | 125.39B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.10 | 79.10B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
669.71 | 40.58B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.10 | 29.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru Inc (VERU) Shares Down Despite Recent Market Volatility - The News Heater
Veru Inc (VERU Stock: A Sea of Opportunity - The InvestChronicle
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Veru (VERU) Projected to Post Earnings on Thursday - MarketBeat
Veru Inc (VERU) is looking forward to a strong quarter - SETE News
What will the future hold for Veru Inc (NASDAQ:VERU) stock? - US Post News
Veru (VERU) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Oppenheimer maintains Veru stock Outperform rating, $5 target - MSN
Veru (VERU) to Release Quarterly Earnings on Thursday - Defense World
Veru shares plunge despite positive data in obesity trial - pharmaphorum
Oppenheimer maintains Veru stock Outperform rating, $5 target By Investing.com - Investing.com Australia
Veru Hopes To Improve The QUALITY Of Drug-Induced Weight Loss - Citeline
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough? - BioSpace
Muscle-building drug improves body composition in obesity trial, Veru says - BioPharma Dive
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Veru's experimental drug helps older obese patients on Wegovy preserve muscle - Reuters
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough - Benzinga
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Veru down 46% despite data for drug preserving lean body mass in Wegovy users - Seeking Alpha
Veru Reports Positive Data From Phase 2b QUALITY Study - Nasdaq
Veru’s enobosarm meets primary endpoint in Phase 2b weight reduction trial - TipRanks
Veru says its drug preserved lean mass in patients taking Wegovy - STAT
Veru Announces Positive Topline Data from Phase 2b QUALITY - GlobeNewswire
Veru's Enobosarm + Wegovy Trial Shows 71% Better Muscle Preservation in Weight Loss Study - StockTitan
Oppenheimer maintains Veru stock Outperform rating as trial nears - MSN
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN
Novo weight-loss data roll out; Veru ‘leans’ in - BioWorld Online
Oppenheimer maintains Veru stock Outperform rating as trial nears By Investing.com - Investing.com Canada
Items Tagged with 'enobosarm' - BioWorld Online
Investors Purchase High Volume of Veru Call Options (NASDAQ:VERU) - Defense World
Veru Target of Unusually High Options Trading (NASDAQ:VERU) - MarketBeat
Investors Buy Large Volume of Veru Call Options (NASDAQ:VERU) - MarketBeat
Jane Street Group LLC Has $74,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
Will QUALITY Add More Weight To Veru Stock? - RTTNews
What is B. Riley's Forecast for Veru Q1 Earnings? - MarketBeat
What is B. Riley’s Forecast for Veru Q1 Earnings? - Defense World
Veru Inc. (NASDAQ:VERU) Shares Purchased by Geode Capital Management LLC - Defense World
Barclays PLC Has $142,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
H.C. Wainwright maintains target on Veru stock post-sale By Investing.com - Investing.com Nigeria
Veru Inc. Sells FC2 Business to Focus on Biopharma - TipRanks
Veru (NASDAQ:VERU) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright maintains target on Veru stock post-sale - Investing.com India
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Veru's (VERU) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Veru Inc. (NASDAQ:VERU) Shares Bought by State Street Corp - Defense World
Biopharma company to cut 90% of jobs after sale - The Business Journals
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):